Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update

Kezar Life Sciences, Inc. (NASDAQ:KZR) was the target of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 953,900 shares, an increase of 11.8% from the August 15th total of 853,600 shares. Based on an average trading volume of 531,900 shares, the short-interest ratio is currently 1.8 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC acquired a new stake in shares of Kezar Life Sciences during the 1st quarter worth $25,000. Mackenzie Financial Corp acquired a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $35,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $63,000. Panagora Asset Management Inc. acquired a new stake in shares of Kezar Life Sciences during the 4th quarter worth $80,000. Finally, Marquette Asset Management LLC acquired a new stake in Kezar Life Sciences in the first quarter valued at about $114,000. 67.90% of the stock is owned by institutional investors and hedge funds.

Kezar Life Sciences Price Performance

NASDAQ KZR remained flat at $0.57 on Monday. The company’s stock had a trading volume of 105,486 shares, compared to its average volume of 611,578. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. The stock’s fifty day moving average is $0.61 and its two-hundred day moving average is $0.73. Kezar Life Sciences has a 52-week low of $0.54 and a 52-week high of $1.32. The stock has a market capitalization of $41.71 million, a P/E ratio of -0.41 and a beta of 0.20.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Research analysts predict that Kezar Life Sciences will post -1.2 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Kezar Life Sciences in a research note on Wednesday, August 14th.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.